About us

Who we are

Dexcel Pharma is the largest private pharmaceutical company in Israel, commercializing an extensive portfolio of branded and generic drugs. Our state-of-the-art R&D and manufacturing facilities enable us to develop and manufacture high-quality products while maintaining long-term partnerships across the value chain

Leadership

Dan Oren

Founder &
Executive Chairman

Ilan Oren

Co-Chief
Executive Officer

Uri Oren

Co-Chief
Executive Officer

Amit Rotem

VP, Human Resources

Eyal Dayan

VP, Research & Development

Itamar Yaron-Enden

VP, Business Development

Jonathan Grushka

VP, General Counsel

Miri Peleg

VP, Chief Information Officer

Ran Kreshtino

VP, General Manager, Dexcel Pharma Israel

Tamar Galanty

VP, Head of Quality

Yaron Erez

VP, Chief Financial Officer

Ygal Seelenfreund

VP, Sales & Marketing, International

Ziv Teresh

VP, Chief Operating Officer

Dan Oren

Founder &
Executive Chairman

Ilan Oren

Co-Chief
Executive Officer

Uri Oren

Co-Chief
Executive Officer

Amit Rotem

VP, Human Resources

Eyal Dayan

VP, Research & Development

Itamar Yaron-Enden

VP, Business Development

Jonathan Grushka

VP, General Counsel

Miri Peleg

VP, Chief Information Officer

Ran Kreshtino

VP, General Manager, Dexcel Pharma Israel

Tamar Galanty

VP, Head of Quality

Yaron Erez

VP, Chief Financial Officer

Ygal Seelenfreund

VP, Sales & Marketing, International

Ziv Teresh

VP, Chief Operating Officer

Manufacturing

Advanced facilities

We are committed to providing patients and partners the highest quality drug products. To ensure that we meet this commitment, we invest in highly advanced, automated manufacturing systems and adopt the latest and technologies at our facilities

Or Akiva

Our capabilities

Manufacturing capabilities are integral to our operations and ongoing success. Our manufacturing sites are highly automated and computer-controlled technologies to optimize production and reduce human error. We produce oral-solid dosage forms using different manufacturing processes and technologies

Jerusalem

Global quality standard

Dexcel holds a sterling reputation with regulators, partners, and customers. Our global supply chain management and responsive customer service ensure product supply consistency, competitive pricing, and timely delivery.

Our manufacturing sites operate at cGMP standards and are approved by the FDA and EMA for commercial supply

Yokneam

Our
STORY
1968
Inception
1980
First international export
1993
New manufacturing facility in Or Akiva
1996
UK and DE subsidiaries establishment
2008
Omeprazole DR OTC US launch
2010
Inauguration and FDA approval of Yokneam Manufacturing site
2013
New R&D center in Jerusalem
2014
First investor in
Roivant Sciences
2018
Formation of
Clexio Biosciences
2021
Formaton of
Dexoligo Therapeutics
2022
Acquisition and establishment of US subsidiary
Our
STORY
1968
1980
1993
1996
2008
2010
2013
2014
2018
2021
2022

Join Us

We strive to deliver medicine better and faster. If you understand how the pharmaceutical industry influences our world, and are eager to create a positive impact, then we invite you to join us

Open positions
white arrow points to the right